ÂÜÀòÂÒÂ×

Carey Gallant is a Senior Analyst in Outcome Capital’s life sciences practice assisting the team in support of a wide range of M&A, corporate finance, and advisory mandates.

Prior to joining Outcome, Carey was an associate in LifeSci Partners’ Investor Relations vertical. While at LifeSci, Carey was responsible for assisting a variety of strategic consulting efforts for early and late-stage healthcare and life sciences companies via tailor-made market research and competitive analysis. Before making his transition into a consulting role, Carey began his career as a life sciences researcher conducting pre-clinical oncology research at Synlogic and Minerva Biotechnologies. During this time, he developed assays to identify anti-inflammatory cytokine marker readouts for immuno-modulation.

Carey received a B.S. in biomedical engineering from the University of Vermont and an MBA/MSF dual degree from Boston College’s Carroll School of Management. In addition to his formal coursework, Carey has also completed valuation and financial modeling course with Wall Street Prep.